ASAli Sahin

Ali Sahin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ali Sahin has a total of 88 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Endoplasmic reticulum stress and apoptosis-associated biomarkers in rheumatoid arthritis: an exploratory case–control study

    by Burcu Yılmaz Isık, Arif Babayigit, Halef Okan Dogan, Ali Sahin

    Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation and progressive joint destruction, leading to functional disability and reduced quality of life. Beyond classical inflammatory pathways, increasing evidence indicates that endoplasmic reticulum (ER) stress and activation of the unfolded protein response (UPR) contribute to immune dysregulation and chronic inflammation in RA. However, the clinical relevance of circulating ER stress-related biomarkers in RA remains insufficiently defined. This study aimed to evaluate serum levels of ER stress-related and apoptosis-associated markers in patients with RA, to assess their ability to discriminate RA from healthy individuals, and to explore their associations with inflammatory parameters and disease activity. This observational case–control study was conducted between 2021 and 2022 at the Rheumatology Clinic of Sivas Cumhuriyet University Faculty of Medicine Hospital. This observational case–control study included 35 patients with RA and 31 age- and sex-matched healthy controls. Serum levels of GRP78, eIF2α, ATF4, CHOP, caspase-3, and caspase-9 were measured using enzyme-linked immunosorbent assay. Disease activity was assessed using the Disease Activity Score-28 (DAS28). Statistical analyses included group comparisons, receiver operating characteristic curve analysis, and Spearman correlation analyses. A total of 67 participants (35 RA, 32 controls) were included. GRP-78, ATF4, eIF2α, caspase-3, and caspase-9 levels were significantly higher in RA patients (all p < 0.01), whereas CHOP levels were comparable between groups (p = 0.103). Caspase-3 demonstrated the highest discriminatory performance (AUC = 0.774, 95% CI: 0.656–0.891; p < 0.001). Caspase-3 and caspase-9 remained independently associated with RA in multivariable analysis. No significant correlations were observed between ER stress markers and DAS28 scores. Circulating ER stress-related apoptotic markers, particularly caspase-3 and caspase-9, were found to be associated with rheumatoid arthritis and may represent exploratory candidate biomarker signals reflecting the potential involvement of ER stress–apoptosis pathways in disease pathophysiology.

  • Open Access

    Genotype-phenotype Interactions and Autoimmune Comorbidities in Adult Familial Mediterranean Fever: A Retrospective Cohort Study of 786 Patients

    by Betül Sarı Kalın, Neşe Çabuk Çelik, Rümeysa Yılmaz Göç, Serpil Albayrak, Ali Şahin

    Background: Familial Mediterranean fever (FMF) is a monogenic autoinflammatory disorder characterised by recurrent febrile attacks and serosal inflammation. Although Mediterranean fever gene (MEFV) gene mutations are central to disease pathogenesis, considerable phenotypic heterogeneity exists and the contribution of autoimmune comorbidities to disease expression remains insufficiently characterised in adult populations. Objective: This study aimed to evaluate genotype-phenotype associations and to assess the frequency and clinical impact of autoimmune comorbidities in a large cohort of adult patients with FMF. Methods: We retrospectively analysed 786 adult FMF patients diagnosed according to the Tel-Hashomer criteria. Demographic characteristics, MEFV mutation profiles, clinical manifestations during attacks, acute-phase reactants, treatment regimens and response to colchicine were systematically recorded. Genetic analyses were performed using sequencing-based methods. Statistical analyses were conducted using Statistical Package for the Social Sciences software. Results: Arthralgia was the most frequent clinical manifestation (89.8%), followed by abdominal pain and myalgia. Homozygous MEFV mutations, particularly M694V homozygosity, were significantly associated with increased disease severity, higher attack frequency and colchicine resistance. Autoimmune comorbidities were identified in 30.4% of patients, with ankylosing spondylitis being the most common (19.8%). Patients with homozygous M694V mutations exhibited higher rates of colchicine resistance ( P = .021) and required interleukin-1 inhibitors more frequently ( P = .003). Conclusion: FMF exhibits marked clinical heterogeneity influenced by both genetic background and coexisting autoimmune conditions. Homozygous M694V mutations are associated with severe disease and treatment resistance. Routine evaluation for autoimmune comorbidities may facilitate individualised treatment strategies in adult FMF patients.

  • Open Access

    Screening of osteoporosis in patients with ANCA-associated vasculitis (AAV) is quite low: results from a country-wide study

    by Tuba Demirci Yildirim, Esra Erpek, Bahar Özdemir Ulusoy, Gullu Sandal Uzun, Ayten Yazici, Rıza Can Kardaş, Duygu Sahin, Duygu Sevinc Ozgur, Timucin Kasifoglu, Melih Kiziltepe, et al.

    Patients with ANCA-associated vasculitis (AAV) are at increased risk of osteoporosis due to multiple disease- and treatment-related factors. However, real-world data on osteoporosis screening practices in this population remain limited. The aim of this study was to assess osteoporosis screening practices and the prevalence of reduced bone mineral density (BMD) in patients with AAV using a nationwide registry, and to identify factors associated with osteoporosis. This nationwide, retrospective, web-based study was conducted using the Turkish Vasculitis Study Group (TRVaS) database, including patients diagnosed with AAV between January 2000 and December 2023. Patients were evaluated for osteoporosis screening using dual-energy X-ray absorptiometry (DXA) and categorized according to BMD status. Clinical characteristics and potential risk factors were analyzed, and multivariable logistic regression was performed to identify independent predictors of osteoporosis. A total of 528 patients were included (median age 56 years [interquartile range 43–66]; 57.8% male). Of these, 36.2% underwent DXA screening; among screened patients, 40.8% had osteoporosis and 38.7% had osteopenia. In multivariable analysis, older age (odds ratio [OR] 1.03, p = 0.020) and the presence of at least one additional osteoporosis risk factor (OR 2.25, p = 0.049) were independently associated with osteoporosis. This nationwide registry-based study highlights a gap between the recognized risk of osteoporosis in patients with AAV and its implementation in real-world clinical practice. These findings underscore the need for improved screening and comprehensive bone health management strategies in this population.

  • Open Access

    Evaluation of the Effect of IL‐1 Antagonists on Pituitary Function

    by Fadime Aktas Koc, Baris Sariakcali, Ali Sahin

    Background: Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disease frequently observed in populations along the Eastern Mediterranean coast, characterized by recurrent fever, abdominal pain, and joint inflammation. The disease results from mutations in the MEFV gene, which plays a critical role in regulating IL‐1β secretion. Mutations in pyrin lead to uncontrolled IL‐1β release, driving FMF’s inflammatory symptoms. IL‐1 inhibitors, such as anakinra, rilonacept, and canakinumab, have been introduced as adjunctive treatments. This paper aims to investigate the effects of IL‐1 inhibitors on pituitary functions in FMF patients. Methods: The study was conducted at Sivas Cumhuriyet University Hospital and included patients who had been using IL‐1 inhibitors for at least 6 months. The control group consisted of patients receiving colchicine treatment only. Blood samples were collected to measure various pituitary and endocrine hormones. Patients with conditions like corticosteroid use, cancer, or hemodialysis were excluded. Hormonal levels were analyzed, and cortisol‐deficient patients underwent a Synacthen test. Results: No significant differences were found in TSH, ACTH, cortisol, LH, estradiol, IGF‐1, or PRL levels between the groups. However, differences were noted in FSH, total testosterone, and GH levels, with higher FSH and GH in the control group and higher testosterone in the experimental group. Conclusions: Although IL‐1 plays a role in hormone secretion pathways, further studies are needed to better understand the effect of IL‐1 antagonists on pituitary function, as no significant adrenal or pituitary insufficiencies were observed.

  • Caspase 3, Caspase 8, Caspase 9, Granzyme-B and Apaf-1 Levels in Familial Mediterranean Fever Patients Treated with Colchicine: Experimental and Theoretical Methods

    by Canan Yilmaz Kapancik, Özlem Demirpençe, Ali Şahin, Serkan Kapancık, Sevtap Bakır, Hande Küçük Kurtulgan, Burak Tüzün

    Familial Mediterranean Fever disease (FMF) is an autosomal recessive genetic disease, as well as a disease that seriously impairs the quality of life, accompanied by the appearance of symptoms such as recurrent high fever, peritonitis and acute synovitis. In FMF disease, a mutation status in the MEFV gene is encountered. The presence of faulty protein synthesis as a result of this mutation mediates the emergence of the disease. It is thought that there may be a condition associated with apoptosis in the pathogenesis of this disease. Apoptosis is a form of cell death in which energy is expended and programmed with great importance in maintaining cellular balance. In this study, the levels of Caspase 3, Caspase 8, Caspase 9, Granzyme B and Apaf 1 from apoptosis-related proteins were analyzed using the ELISA method in serum samples obtained from FMF patients treated with colchicine and a healthy control group. There was no statistically significant difference between Caspase 3 (P=0, 111), Granzyme B (P=0, 304), Apaf 1 (P=0, 097) and Caspase 8 (P=0, 245) levels in the FMF patient group compared to the control group (p >0, 05). A statistically significant difference was found in the Caspase 9 levels in the FMF patient group (P=0.001) compared to the control group (p


  • Open Access

    Evaluation of Pan-Immune-Inflammation Value (PIV) as a Predictive Biomarker for Psoriatic Arthritis in Patients with Psoriasis

    by Funda Koç Babayiğit, Ramazan Yüceer, Arif Babayiğit, Ali Şahin

    Objective: Psoriasis (PsO) is a chronic inflammatory dermatosis that affects a significant portion of the global population and is associated with various comorbidities, including psoriatic arthritis (PsA). PsA develops in 20– 30% of psoriasis patients and significantly impacts patient quality of life. Currently, early detection of PsA remains challenging, with no reliable, non-invasive biomarker for risk assessment. This study aims to evaluate the utility of pan-immune-inflammation value (PIV), along with other inflammatory indices, in predicting the development of PsA in patients with PsO. Methods: A retrospective analysis was conducted on 101 psoriasis patients (51 PsO, 50 PsA). Hematological parameters, including neutrophil, lymphocyte, monocyte, and platelet counts, were collected, and various inflammatory indices (PIV, SIRI, SII, NLR) were calculated. The diagnostic performance of these indices was assessed using Receiver Operating Characteristic (ROC) curve analysis. As a retrospective, double-center study with a limited sample size, the findings should be interpreted with caution and validated in larger, prospective cohorts. Results: The study found significant differences between PsA and PsO patients in terms of inflammatory indices, with higher PIV, SII, SIRI, and NLR levels observed in PsA patients. The diagnostic performance of PIV (AUC 0.63), SII (AUC 0.70), SIRI (AUC 0.64), and NLR (AUC 0.71) indicated that elevated levels of these indices could serve as potential markers for PsA risk. Additionally, PIV was significantly correlated with SII, SIRI, and NLR levels. Conclusion: PIV and other inflammatory indices, particularly NLR and SII, show promise as biomarkers for predicting the onset of PsA in patients with PsO. These findings may aid in early identification and timely intervention for PsA, improving patient outcomes and informing treatment strategies.


  • Altered Lipid Profiles and Increased Cardiovascular Risk in Behçet's Disease: A Link Between Low HDL-C and Neurological Involvement

    by Serkan Bolat, Selda Özer, Demet Kablan, Betül Köksöken, Ali Şahin, Gökmen Zararsız, Halef Okan Dogan

    This study aimed to understand the relationship between lipid levels and inflammation in Behçet’s disease (BD) and to evaluate the possible effects of lipid profiles on the course of the disease. A total of 168 people, including 84 patients and 84 controls, were included in the study. The lipid profiles and inflammatory marker levels of the individuals in the study group were recorded retrospectively, and a comparative analysis was performed between the groups. Triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), TG/high-density lipoprotein cholesterol (HDL-C) ratio, TC/HDL-C ratio, interleukin-6 and C-reactive protein were found to be higher in patients than in controls. However, HDL-C values were lower in the control group. In addition, lower HDL-C levels were found in the neuro-Behçet group. There was no statistically significant relationship between serum lipids and inflammation-related biomarkers. In conclusion, we think that regular monitoring of lipid profiles and TG/HDL-C levels and interventions to increase HDL-C levels may help reduce the neurologic complications associated with Behçet’s disease.

  • Open Access

    AB0893-HPR TREATMENT SATISFACTION, EXPECTATIONS, PATIENT PREFERENCES, AND CHARACTERISTICS IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA): TURKISH COHORT RESULTS OF THE SENSE STUDY

    by U. Kalyoncu, A. Kucuk, G. Sargin, F. Ozdener, S. Yolbaş, B. Yurttas, S. Turan, G. Kimyon, A. Sahin, S. Yilmaz, et al.

    Background: Suboptimal control of RA may lead to severe and progressive articular damage, loss of function, and deterioration of the quality of life (QoL). Objectives: To assess treatment satisfaction, sociodemographic, clinical, health care resource utilization, and QoL characteristics of patients with sub-optimally controlled RA and treated with conventional synthetic and/or biologic DMARDs. Methods: This study was an international, multicenter, cross-sectional, non-interventional study. Adult RA patients with moderate to severe disease activity (DAS28>3.2) were enrolled. Patient satisfaction was evaluated with Treatment Satisfaction Questionnaire for Medication (TSQM, version 1.4) with a scale ranging from 0 (indicating poor satisfaction) to 100 (indicating perfect satisfaction). Patients were questioned regarding treatment adherence, patient preferences, and expectations. Workability was evaluated using Work Productivity and Activity Impairment Questionnaire-Rheumatoid Arthritis (WPAI-RA, version 2.0). Short Form 36 (V2) survey were performed to all patients. Results: One hundred sixty-four patients were included in the study and most (78.0%) were female. The median age was 57.0 years, ranging between 22.0 and 84.0 years. Half of the patients (50.6%) were primary school graduates and 6.1% were unemployed due to RA and seeking work. Median time since RA diagnosis was 8.0 years and mean (±SD) DAS28-CRP score was 4.8 (±1.0). Mean total activity impairment was 54.9% (±27.4). In the past 3 months from enrollment, the mean number of healthcare professional and emergency room visits were 1.8 (±1.1) and 1.8 (±1.3), respectively. Mean number and length of hospitalizations in the previous 3 months were 1.1 (±0.3) times and 8.3 (±7.2) days, respectively. Mean TSQM scores were 53.5 (±21.4) for effectiveness, 86.0 (±26.7) for side effects, 67.8 (±16.5) for convenience, and 57.7 (±22.0) for global satisfaction. The leading expectation was ‘lasting relief of RA symptoms’ (mean score: 5.8). Preferred time until the effect of onset was ‘up to 1 week’ for 76.2% of the patients. Most of the patients (57.9%) preferred oral administrations and the most preferred frequency of administration was ‘once per day’ (46.3%). Mean physical and mental component summary scores for Short Form 36 (V2) survey were 37.9 (±8.3) and 40.1 (±10.7). Conclusion: Two-thirds of the patients with RA who have suboptimal responses are not satisfied with their treatments. Moreover, oral and once-daily treatment approaches stand out in patient preferences. Finally, suboptimal control leads to deterioration in clinical characteristics, workability, and QoL of patients with RA. Acknowledgements: The design, study conduct, and financial support for the study were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication. All authors have received research funding for this study. The authors wish to thank B. Murat Ozdemir of Monitor CRO for medical editing and reviewing services of this manuscript. AbbVie provided funding to Monitor CRO for this work. Disclosure of Interests: Umut Kalyoncu Speakers bureau: AbbVie, Pfizer, UCB, Novartis, and Janssen, Consultant of: AbbVie, Pfizer, UCB, Novartis, and Lilly, Grant/research support from: AbbVie, Pfizer, and Janssen, Adem Kucuk Speakers bureau: AbbVie, Gokhan Sargin: None declared, Fatih Ozdener Speakers bureau: UCB, Nutricia Advanced Medical Nutrition, Grant/research support from: Nutricia Advanced Medical Nutrition, Servet Yolbaş Speakers bureau: AbbVie, UCB, Pfizer, and MSD, Berna Yurttas: None declared, Sezin Turan: None declared, Gezmiş Kimyon Speakers bureau: AbbVie, Amgen, Pfizer, Novartis, UCB, MSD, Johnson and Johnson, and Celltrion, Consultant of: Amgen, and Pfizer, ALI SAHIN Speakers bureau: Roche, Pfizer, and AbbVie, Consultant of: Roche and Pfizer, Sedat Yilmaz Speakers bureau: UCB, Pfizer, AbbVie, MSD, Novartis, and Celltrion, Consultant of: Pfizer and Novartis, Ridvan Mercan Speakers bureau: AbbVie, Novartis, MSD, Pfizer, UCB, Roche, Amgen, and Celltrion, Consultant of: Novartis, MSD, Pfizer, and Celltrion, Hakan Emmungil Speakers bureau: AbbVie, Pfizer, Novartis, and MSD, Muhammet Çinar Speakers bureau: AbbVie, Pfizer, Celltrion, UCB, Amgen, Novartis, and MSD, Grant/research support from: AbbVie, Pfizer, Celltrion, UCB, Amgen, Novartis, and MSD, İlhan Sezer Speakers bureau: AbbVie, Pfizer, MSD, Novartis, Celltrion, UCB, Amgen, and Abdi Ibrahim, Consultant of: AbbVie, Pfizer, MSD, Novartis, Celltrion, UCB, Amgen, and Abdi Ibrahim, Grant/research support from: AbbVie, Pfizer, MSD, Novartis, Celltrion, UCB, Amgen, and Abdi Ibrahim, Timuçin Kaşifoğlu Speakers bureau: AbbVie, Amgen, Roche, MSD, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Roche, MSD, Novartis, Pfizer, and UCB, Fulya Cosan Speakers bureau: AbbVie, Pfizer, Novartis, UCB, and MSD, Taskin Senturk: None declared, Nevsun Inanc Speakers bureau: AbbVie, UCB, Novartis, Pfizer, Roche, Lilly and MSD, Consultant of: Roche and Pfizer, Grant/research support from: Roche and Pfizer

  • Patients’ concerns regarding biological agents in rheumatology

    by Yavuz Pehlivan, Nurdan Orucoglu, Seda Pehlivan, Gezmis Kimyon, Orhan Zengin, Adem Kucuk, Ali Sahin, Nazmiye Tomas, Mustafa Ferhat Oksuz, Bunyamin Kisacik, et al.

    Objective: The potential side effects of biological agents may increase the anxiety levels of patients and influence not only their desire to use these therapies but also their concordance to treatment. This study aimed to determine the level and prevalence of drug‐related concern in patients treated with biological agents and to acquire additional information regarding the related causes.Materials and Methods: A total of 1134 patients who were using biological agents for at least 3 months with a diagnosis of rheumatic diseases were enrolled. General anxiety levels were evaluated using the State‐Trait Anxiety Inventory (STAI).Results: The most common cause for drug‐related concerns was the potential side effects of the drugs (59.5%). Among the potential side effects, cancer risk was the most common cause for concern (40.1%), followed by the risk of tuberculosis activation (30.7%). Anxiety levels were higher in patients who experienced side effects than in other patients, and this difference was statistically significant (P < 0.05). STAI trait and state scores were moderately correlated with anxiety levels related to the drug (P < 0.001).Conclusion: Anxiety related to biological agents may significantly affect the patients’ anxiety levels. Awareness regarding the patients’ concerns and expectations related to the drug is important to ensure drug adherence and concordance to treatment.


  • Open Access

    A Rare Mediastinal Tumor: Thymolipoma

    by Isa Döngel, Hakan Imamoğlu, Ali Feyzullah Şahin, Salih Yıldırım, Mehmet Bayram